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ABSTRACT 
Objective: The natural product Momordica cymbalaria Fenzl has been in use considerably because of its antidiabetic activity. In this work, we have 
investigated the protective action of one of its phytoconstituent, a saponin, in peripheral neuropathy–a diabetic complication.  
Methods: The saponin was isolated and identified by preparative high-performance liquid chromatography (preparative HPLC) and thin layer 
chromatography TLC). High glucose (56 mM)-mediated neuropathy was induced in NB-41A3 mouse neuroblastoma cells and the neuroprotective 
activity of the saponin was assessed by evaluating its effect on the two polyol pathway enzymes–aldose reductase (AR) and sorbitol dehydrogenase 
(SDH). The accumulation of intracellular sorbitol, activity of Na+K+-ATPase and production of pro-inflammatory cytokines IL-6, IL-1β and TNF-α 
were also investigated.  
Results: The results showed a significant reduction in AR activity and intracellular accumulation of sorbitol on saponin treatment. Improvement in 
Na+K+-ATPase activity was evident with a noteworthy reduction in IL-6, IL-1β and TNF-α production.  
Conclusion: These results suggest that the saponin possesses neuroprotective activity in diabetic peripheral neuropathy. 
Keywords: Diabetic peripheral neuropathy (DPN), Saponin of Momordica cymbalaria (SMC), Neuroblastoma cells, Aldose reductase, Sorbitol 
dehydrogenase, Na+K+-ATPase 
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
Diabetic peripheral neuropathy (DPN) is a multifactorial disorder 
arising from hyperglycemia and/or insulin deficiency. It is 
characterized by a complex pathogenetic network of interrelated 
metabolic, neurotrophic, and vascular defects [1]. Diabetic 
neuropathy influences all peripheral nerves including sensory and motor 
neurons and the autonomic nervous system. As all the organs and 
systems are innervated, it can affect all. It usually results in sensory 
abnormalities such as burning sensations, hyperalgesia, allodynia and 
dysesthesia, leading to alteration in patient’s quality of life [2]. 
The polyol pathway of glucose metabolism plays a crucial role in the 
development of neuropathy [3]. Polyol pathway overactivity [4, 5] 
and increased non-enzymatic glycation [6, 7] has been implicated in 
diabetic neuropathy. It is a two-step metabolic pathway in which 
glucose is reduced to sorbitol by the enzyme aldose reductase, which 
is then converted to fructose by sorbitol dehydrogenase. The first 
enzyme, aldose reductase (AR), requires NADPH as a cofactor, and 
the second enzyme sorbitol dehydrogenase (SDH) needs NAD+. 
During hyperglycemia, sorbitol accumulates in AR-containing 
tissues, presumably because oxidation by SDH is rate limiting and 
because polyols do not readily diffuse across cell membranes it was 
thought that accumulation of sorbitol produces osmotic that leads to 
diabetic lesions [8, 9]. Treatment with AR inhibitors in animal 
models has shown prevention of various diabetic complications 
including cataract, neuropathy, and nephropathy [10]. It is reported 
that AR inhibitor epalrestat prevents high glucose–induced smooth 
muscle cell proliferation and hypertrophy [11] thereby preventing 
their dysfunction and remodeling [12].  
Na+K+-ATPase is an integral membrane protein which is responsible 
for providing and preserving the electrochemical gradient of Na and 
K ions between two sides of the plasma membrane. Decrease in 
Na+K+-ATPase activity in peripheral nerves plays an important role 
in the development of diabetic neuropathy [13]. Diabetic conditions 
are associated with chronic low-grade inflammation, evidenced by 
raised pro-inflammatory cytokines which include IL-1β, IL-6 and TNF-
α which contribute to the pathogenesis of diabetic neuropathy [14].  
Plants constitute a rich source of bioactive chemicals. Since many 
plants are largely free from adverse effects and have excellent 
pharmacological actions, they could possibly lead to the 
development of new classes of safer antidiabetic agents or diabetic 
complication resolving agents. Momordica cymbalaria 
(Cucurbitaceae) has been found to possess Type I [15] and Type II 
[16] anti-diabetic activities. The current study was conducted to 
investigate into the in vitro effects of the saponin of Momordica 
cymbalaria (SMC) on polyol pathway, Na+K+-ATPase activity and IL-
1β, IL-6 and TNF-α in NB-41A3 mouse neuroblastoma cells.  
MATERIALS AND METHODS 
Plant material  
The fresh roots of Momordica cymbalaria Fenzl were collected from 
Gadag district of Karnataka, India, and was identified and 
authenticated by the Department of Botany, Bangalore University, 
Bangalore, India (voucher No. 18122003). 
Reagents  
Fetal Bovine serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), Phosphate Buffered Saline 
(PBS), Ham’s F12 medium, glycine, EDTA, Glucose, antibiotics, D-
fructose, Triethanolamine, β-Nicotinamide Adenine Dinucleotide, 
reduced form (β-NADH), Bovine Serum Albumin (BSA), Zymefree®, 
NADPH, Lithium sulphate, DL-glyceraldehyde, sorbitol, acetonitrile, 
adenosine triphosphate (ATP), ferrous ammonium sulphate, 
thiourea and ammonium molybdate were obtained from Hi-Media 
Laboratories Ltd., Mumbai, India. Protease inhibitor cocktail was 
obtained from (Sigma-Aldrich, Bangalore, India). IL-1β, IL-6 and 
TNF-α standard, IL-1β, IL-6 and TNF-α primary antibodies and HRP-
conjugated secondary antibody were obtained from Santa Cruz 
Biotechnology, USA. 
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Extraction and isolation  
The powdered roots were Soxhlet extracted with methanol. 
Methanolic extract was saponified and hydrolyzed with 0.5 N KOH in 
distilled water for 1-2 h. The unsaponified fraction was then 
extracted with diethyl ether. The upper organic layer was extracted 
with diethyl ether for complete separation of sterols. Ether and 1 % 
aqueous KOH was added, and the ether layer was separated. The 
ether was distilled off and 6 ml acetone was added and shaken. The 
solvent was completely removed, and the residue was dried to a 
constant mass. To confirm the presence of triterpenoid saponins, 
high-performance thin layer chromatography (HPTLC) was 
performed on Silica gel 60 F254 using chloroform: glacial acetic acid: 
methanol: water (16:8:3:2) as mobile phase and spraying with the 
anisaldehyde-sulphuric acid reagent. For further purification, the 
saponins so obtained were chromatographed on preparative HPLC 
(Agilent 1260 Infinity) using a C18 column (5 µm) and UV detector; 
flow rate was 5 ml/min. The mobile phase used was acetonitrile: 10 
mM K2HPO4 buffer (pH 5.8)::70:30 for the first 10 min, changed to 
90:10 for the next 10 min. Pure diosgenin (Yarrow chem, Mumbai) 
was used as a standard. 
Cell culture and cytotoxicity assessment of the saponin  
NB-41A3 mouse neuroblastoma cells were obtained from National 
Centre for Cell Science (NCCS), Pune, India. The cells were grown in 
Ham’s F12 medium supplemented with 10 % fetal bovine serum, 50 
IU/ml penicillin, 25 μg/ml streptomycin and 2.5 µg/ml amphotericin 
B. The assessment of cytotoxicity of SMC on NB-41A3 cell line was 
done by the reduction of 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to formazan [17]. Cells were 
seeded in a 96-well plate (5-10×103 cells/well) and left to attach on 
to the substrate overnight before being exposed to SMC, and 
incubated at 37 °C for 24 h. The cells were then treated with various 
concentrations of SMC (500, 250, 125, 62.5, 31.25, 15.625, 7.813, 
3.906 & 1.953 µg/ml) and incubated for 36 h. After 36 h 50 µl MTT 
(5 mg/ml) solution was added to each well and the cells were 
incubated in the dark at 37 °C for an additional 4 h. Thereafter, the 
medium was removed, the formazan crystals were dissolved in 200 
µl of DMSO and 25 µl of glycine buffer (pH 10.5), and the absorbance 
was measured at 570 nm in a microplate reader. The percentage cell 
viability was calculated. 
High glucose-induced neurotoxicity 
For neurotoxicity assay, cells were seeded in a 96-well plate (5-
10×103 cells/well) and left to attach onto the substrate overnight. 
Then the cells were exposed to high glucose (56 mM) in the 
presence and absence of SMC (10, 25, 50, 75 & 100 µg/ml), and 
incubated for 36 h. After incubation, assessment of cell viability was 
done by MTT assay [17].  
Polyol pathway–AR and SDH activities, and sorbitol 
accumulation 
Cells plated onto 12-well plate, each well containing 5×105 cells, 
growth medium being Ham’s F12 containing 10 % FBS. Cells were 
incubated for 24 h to facilitate attachment. After incubation old 
medium was replaced with fresh one and treatment started. The 
cells were grouped as– 
Group 1: Normal control–cells in growth medium (normal glucose, 
5.5 mM) 
Group 2: High glucose control–cells in high glucose (56 mM) 
medium 
Group 3: Treated group–high glucose control+50 µg/ml SMC 
Group 4: Standard group–high glucose control+1µM epalrestat [11] 
Cells were incubated for 72 h. After incubation, medium from each 
well was removed and cells adhering to the plate were lysed using 
ice-cold cell lysis buffer containing 1x Triton-X-100 (1 %), 50 mM 
Tris-HCl (pH 7.4), 5 mM EDTA, 150 mM NaCl and a protease 
inhibitor cocktail of aprotinin, benzamidine, leupeptin, pepstatin A, 
and PMSF. Entire well contents were centrifuged at 10,000 rpm for 5 
min at 4 °C. The supernatants from every tube were collected and 
assayed for AR & SDH activities and sorbitol accumulation by HPLC. 
For AR activity, 0.7 ml of phosphate buffer (0.067 M), 0.1 ml of 
NADPH (25×10-5 M), 0.1 ml of homogenate supernatant, 0.1 ml of 
DL-glyceraldehyde (substrate) (5×10-4 M) were taken in a cuvette. 
The absorbance of the final solution was taken against a reference 
cuvette containing all components except the substrate, DL-
glyceraldehyde. The enzymatic reaction was started by the addition 
of the substrate, and the absorbance (OD) was recorded at 340 nm 
for 3 min at 30 s interval. AR activity was expressed as 
µmoles/min/ml [18]. 
For the determination of SDH activity, 2.35 ml of 100 mM 
Triethanolamine buffer pH 7.6, 0.5 ml of 1.1 M D-fructose solution 
and 0.05 ml of 12.8 mM β-NADH solution were added to a cuvette 
and mixed by inversion to equilibrate to 25 °C. Using a 
thermostatted spectrophotometer, the A340 nm is monitored until 
constant and, then 0.1 ml of the supernatant was added to start the 
reaction. A reference cuvette was maintained containing all 
components except 1 % BSA in place of the homogenate 
supernatant. The decrease in A340 nm was recorded for 5 min at 30 s 
interval. SDH activity was expressed as µmoles/min/ml [19].  
The separation and quantification of samples and standards were 
performed using an Agilent 1120 binary HPLC pump equipped with 
a dual wavelength absorbance detector, and an EZChrome software. 
Separations were performed on a Waters Sunfire® C18 reversed-
phase column (250 mm×4.6 mm, 5 µm, Milford, MA) and peak 
detection was performed at 231 nm. A gradient elution using H2O 
and acetonitrile and a flow rate of 1.0 ml/min was maintained 
throughout the separation. Injection volume used was 25 µl. Sorbitol 
reference standard (Sigma-Aldrich, India) was used of concentration 
100 µg/ml. An initial solvent composition of 30 % H2O and 70 % 
acetonitrile was maintained at injection and held for 2 min. At 2 min 
the proportion of acetonitrile was increased linearly to 87.5 % over 
a 2 min period then held for 2 min. At 4 min the proportion of 
acetonitrile was increased linearly to 95 % over 1 min and held for 1 
min. At 5 min, the elution solvent was returned to 87.5 % over a 1 
min period followed by to 80 % for the next 1 min and then to 70 % 
in the next one min. The system is allowed to equilibrate for 5 min 
prior to starting the next injection [20]. 
AR and SDH expression analysis by ELISA 
The effect of SMC on the expression of AR and SDH in a 
hyperglycemic state (56 mM glucose) was evaluated by enzyme-
linked immunosorbent assay (ELISA). The cell lysate was incubated 
with anti-AR antibody [(E-14) 1:2000; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA] & anti-SDH antibody [(H-284) 1:2000; Santa 
Cruz Biotechnology, Santa Cruz, CA, USA] followed by rabbit anti-
mouse IgG-HRP (1:5000; sc-358914, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA).  
Na+K+-ATPase activity 
Cells were incubated for 72 h. After incubation, cells adhering were 
lysed using ice-cold cell lysis buffer containing 1x Triton-X-100 (1 
%), 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 150 mM NaCl and a 
protease inhibitor cocktail of aprotinin, benzamidine, leupeptin, 
pepstatin A, and PMSF. The homogenate was used for further 
analysis. The Na+ K+-ATPase activity was assayed at 37 °C in an 
incubation mixture containing 30 mmol/l Tris-HCl pH 7.4, 0.1 
mmol/l EDTA, 50 mmol/l NaCl, 5 mmol/l KCl, 6 mmol/l MgCl2, and 1 
mmol/l ATP in the presence or absence of 0.5 mM ouabain [21]. 
After pre-incubating the homogenate for 10 min at 37 °C, the 
reaction was started by the addition of ATP and stopped with 50 μL 
of TCA (30 %) after 20 min. To determine inorganic phosphate (Pi) 
in the supernatant, 750 µl of a reducing solution containing 3.5 % 
ferrous ammonium sulphate, 1.0 % thiourea, and 1.0 % H2SO4 and 
150 µl of an ammonium molybdate solution containing 4.4 % 
ammonium molybdate and 9 % of H2SO4 were added to 750 µl of the 
solution to be assayed. After 10 min incubation at room 
temperature, the absorbance at 750 nm was measured with a 
spectrophotometer [22]. Na+ K+-ATPase activity was calculated as 
the difference between the presence or absence of ouabain-sensitive 
Na+ K+-ATPase activity. 
Samaddar et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 4, 229-235 
231 
Measurement of pro-inflammatory cytokines IL-6, IL-1β and 
TNF-α 
The concentration of the cytokines in the culture supernatant was 
determined by ELISA. The primary detecting antibodies for IL-6 [(R-
19) 1:1500; Santa Cruz Biotechnology, Santa Cruz, CA, USA], IL-1β 
[(H-153) 1:1500; Santa Cruz Biotechnology, Santa Cruz, CA, USA] 
and TNF-α [(M-18) 1:1500; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA] were used. Rabbit anti-mouse IgG-HRP (1:5000; sc-
358914, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used 
for final detection.  
Statistical analysis 
The results are expressed as mean±standard error of mean (SEM) 
and one-way analysis of variance (ANOVA) followed by Dunnett’s 
test was used to determine statistical significance. Values of p<0.001 
were considered to be significantly different from each control.  
RESULTS 
Extraction and isolation of SMC 
High-performance thin layer chromatography (HPTLC) of the extract 
indicated the presence of triterpenoid saponin. High-performance 
liquid chromatogram of the extract yielded two peak signals at 2.5 
and 3.0 min respectively against the Standard diosgenin at 3.5 min 
(fig. 1). The second component which corresponds to the standard 




Fig. 1: HPLC chromatograms of standard diosgenin (A) and 
saponin of Momordica cymbalaria (B). The retention times (RT) 
of both were same (3.6 min) 
 
Cytotoxicity assessment and high glucose-induced neuro-
toxicity 
To evaluate the cytotoxicity of SMC, NB-41A3 cells were incubated in 
the presence of a series of SMC concentrations. It was found that the 
saponin did not exert significant cytotoxicity on the cells. Even at the 
highest test concentration of 500 µg/ml, 81.31 % viability of cells 
was evident (fig. 2). When the cells were exposed to 56 mM glucose 
for 36 h decrease in cell viability was evident as a result of cell death. 
However, cell survival increased when treated with SMC in a dose-
dependent fashion when compared with the diabetic control (fig. 3). 
This reveals the ability of SMC to protect the cells from glucose 
neurotoxicity and impart normal viability & growth. 
AR and SDH activities and sorbitol accumulation 
Neuroblastoma cells were cultured in the presence of high glucose 
and SMC to evaluate its effect on the activities of AR and SDH, and 
also on sorbitol accumulation. Saponin of Momordica cymbalaria at 
50 µg/ml has shown significant AR inhibition activity (p<0.001) 
when compared to high glucose control (group 2). The AR inhibition 
activity of SMC is, in fact, comparable to the activity of epalrestat, the 
standard AR inhibitor. SMC also inhibited SDH activity as compared 
to the controls.  
However, this inhibitory activity was not found to be significant. 
Epalrestat, too, did not show any significant SDH inhibition activity 
(fig. 4). Aldose reductase and SDH activities for the normal control 
without glucose were not detected. 
 
 
Fig. 2: Cytotoxicity assessment of SMC by MTT assay. Values are 




Fig. 3: Effect of SMC in high glucose-induced neurotoxicity in 
NB-41A3 cells. A dose-dependent survival mediated by the SMC 
is seen. Values are expressed as mean±SEM (n=6). *** p<0.001 
compared with the normal control, ### p<0.001 compared with 
the high glucose control 
 
Saponin of Momordica cymbalaria has also been found to 
significantly reduced the formation of sorbitol (p<0.001) under 
hyperglycemic state when compared to high glucose control group. 
The activity has been found to comparable to that of the standard 
drug epalrestat. However, sorbitol remained undetected in the 
normal control group without glucose (fig. 5). 
The results indicate over-expression of AR and SDH in a 
hyperglycemic condition while treatment with SMC significantly 
reduced AR expression as compared to the high glucose control 
(p<0.001).  
However, reduction in SDH expression was not identified 
significantly. Reduction in AR expression was found to be profound 
for epalrestat while no significant effect was seen in the inhibition of 
SDH expression (fig. 6). These results in conjunction with those of 
the AR and SDH activities are indicative of the AR inhibiting 
property of SMC. 
Samaddar et al. 




Fig. 4: Effect of SMC of aldose reductase (A) and sorbitol 
dehydrogenase (B) activities. Values are expressed as mean±SEM 
(n=6). *** p<0.001 compared with the normal control; ### p<0.001 
compared with the high glucose control, ns = statistically not 
significant when compared with high glucose control 
 
 
Fig. 5: Effect of SMC on the intraneural accumulation of sorbitol 
under high glucose condition. *** p<0.001 compared with the 
normal control; ### p<0.001 compared with the high glucose 
control. AR and SDH expression 
 
The membrane Na+K+-ATPase activity was found to be significantly 
less for cells maintained in a high glucose environment as compared 
to the normal control (p<0.001). 
 
 
Fig. 6: Effect of SMC on the expression of aldose reductase (A) and 
sorbitol dehydrogenase (B) by NB-41A3 cells maintained in high 
glucose (56 mM). Values are expressed as mean±SEM (n=6). *** 
p<0.001 compared with the normal control; ### p<0.001 compared 
with the high glucose control, #p<0.05 compared with the high 
glucose control, ns = statistically not significant when compared 
with high glucose control. Na+K+-ATPase activity 
 
Improvement in the activity was evident (fig. 7) significantly in cells 
treated with SMC (50 µg/ml) while epalrestat was not found to 
restore the activity, leaving an insight that epalrestat may not have 
any effect on Na+K+-ATPase.  
 
 
Fig. 7: Effect of SMC on Na+K+-ATPase activity in NB-41A3 cells 
maintained in high glucose (56 mM). Values are expressed as 
mean±SEM (n=6). *** p<0.001 compared with the normal control; 
### p<0.001 compared with the high glucose control, ns = 
statistically not significant when compared with high glucose 
control 
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Measurement of IL-6, IL-1β and TNF-α 
Assessment of the anti-inflammatory activity of SMC was done on 
NB-41A3 cells maintained in high glucose (56 mM) environment. It 
was found that the production of all three pro-inflammatory 
cytokines viz., IL-6, IL-1β and TNF-α was increased considerably by 
the cells in high glucose as compared to those in a normoglycemic 
(5.5 mM) state. However, treatment with SMC has significantly 
suppressed the production of the cytokines as compared to the high 





Fig. 8: Effect of SMC on the production of inflammatory 
cytokines viz., IL-6 (A), IL-1β (B) and TNF-α (C) in NB-41A3 cells 
maintained in high glucose (56 mM). Values are expressed as 
mean±SEM (n=6). *** p<0.001 compared with the normal 
control; ### p<0.001, ## p<0.01 and # p<0.05 compared with the 
high glucose control 
DISCUSSION 
Diabetic peripheral neuropathy represents a state of complication 
associated with chronic hyperglycemia influencing all peripheral 
nerves including sensory and motor neurons and the autonomic 
nervous system characterized by pain, paresthesia, hyperesthesia, 
dysesthesia, proprioceptive defect, loss of sensation, muscle 
weakness and atrophy [23]. The polyol pathway has been found to 
be a major contributor in the development of neuropathy. Reduced 
conduction velocity has been found to develop in motor and sensory 
nerves in diabetic animals [24]. The deficit develops between 2 and 
3 w after diabetes induction in rats, has no visible structural 
correlates and is readily reversible on the establishment of 
normoglycemia with insulin [25]. The conduction deficit is also 
prevented or reversed by treatment with an aldose reductase 
inhibitor [26]. The current study has been undertaken to establish 
the neuroprotective effect of a saponin isolated from Momordica 
cymbalaria. Even though the general anti-hyperglycemic activity of 
Momordica cymbalaria has been studied by few [27, 28] but the 
neuroprotective activity, in specific, has never been attempted but 
only by us [29]. Neurons have a constantly high glucose demand, 
cannot afford anaerobic and glycolytic bursts and have a physiology 
that cannot accommodate episodic glucose uptake under the 
influence of insulin. Hyperglycaemia in diabetes causes up to four-
fold increase in neuronal glucose levels. If this is persistent, or if 
such episodes are regular events, then intracellular glucose 
metabolism leads to neuronal damage, or glucose neurotoxicity [30]. 
The SMC has shown to protect the cells in the presence of high 
glucose as a dose-dependent viability of cells was observed. Ninety-
three percent cells were viable at 100 µg/ml of SMC against a 
meager 21.5 % of diabetic control. Chronic hyperglycemia offers a 
plethora of pathophysiological mechanisms that give rise to 
neuropathy. Polyol pathway activation due to increased glucose is 
one such that leads to overexpression of aldose reductase [31] 
which in turn leads to accumulation of sorbitol in the nerve tissue 
thereby causing neuropathic pain [32].  
Many studies with experimental animals suggest that inhibition of 
AR could be effective in the prevention of neuropathy [4, 5]. Our 
findings of experiments with AR & SDH activities suggest that SMC 
significantly inhibited AR activity as compared to the diabetic 
control. Expression analysis of AR and SDH by ELISA also showed a 
significant drop in AR concentration in cells treated with SMC as 
compared with the diabetic control. Elevated expression of AR was 
found in IMS32 Schwann cells in the presence of high glucose (30 & 
56 mM) when measured by Western blotting [31]. However, neither 
an attenuation of SDH activity nor any reduction in SDH expression 
was observed upon SMC treatment as compared to the AR. This 
behavior gives us an impression that the SDH inhibition property of 
SMC is probably insignificant. In fact, studies involving the 
evaluation of a SDH inhibitor have found that SDH inhibition does 
not offer an effective approach for the treatment of diabetic 
neuropathy and is adverse rather than beneficial [33]. Aldose 
reductase overexpression results in accumulation of intracellular 
sorbitol which being impermeable causes hyperosmotic stress. Our 
study involving measurement of intracellular accumulation of 
sorbitol using HPLC showed a significant reduction in sorbitol 
accumulation in the cells treated with SMC as compared to the 
diabetic control. This activity, which is comparable to that of 
epalrestat, suggests the possibility of SMC to be considered as a 
therapeutic candidate in neuropathic pain, calling for further 
investigations to be done. 
Na+K+-ATPase is critical for the membrane potential, and many 
transports, a change in its activity would have profound 
consequence in these tissues. Streptozotocin-treated diabetic 
rodents are animal models used to assess metabolic and 
physiological changes induced by insulin-dependent diabetes. 
Among the diabetes-induced metabolic changes, disturbances of 
Na+K+-ATPase activity have been widely reported [34]. 
Hyperglycemia, through the activation of PKC, is thought to reduce 
Na+K+-ATPase activity, resulting in decreased nerve conduction and 
nerve regeneration [35]. Interestingly, it has been found that Na+K+-
ATPase gene (ATP1 A1) polymorphism allows diabetes to induce a 
greater impairment of Na+K+-ATPase activity which could in turn 
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favour the development of neuropathy [36]. The saponin of 
Momordica cymbalaria has been found to increase the Na+K+-ATPase 
activity as compared to the diabetic control. Other authors have also 
reported reversal of Na+K+-ATPase activity reduction in diabetic 
animals after treatment with curcumin [37].  
All the characterized classical pathways like polyol pathway, PKC 
pathway, MAPK pathway, and increased production of AGEs could 
directly or indirectly initiate and progress the production of 
inflammatory mediators [38]. Hyperglycemia leads to the formation 
of Advanced Glycated End (AGEs) products due to non-enzymatic 
glycation of proteins that act on various receptors present on 
microglia and macrophages stimulate production of cytokines like 
IL-1, IL-6, IL-1β, TNF-𝛼𝛼, chemo attractant protein-1, C-reactive 
protein and chemokines like CCL-2, CXC, and so forth [39]. We have 
evaluated the ability of SMC to suppress neuroinflammation by 
looking into its effect on the production of inflammatory cytokines 
viz., IL-6, IL-1β and TNF-𝛼𝛼 by neuroblastoma cells maintained in 
high glucose. The diabetic control showed increased production of 
all the three cytokines than the normal control whereas SMC 
treatment has been found to reduce the production of all cytokines 
significantly as compared to the diabetic control. It can be clearly 
concluded that SMC possesses ability to reduce neuroinflammation 
and hence, neuropathic pain. Neuroinflammation has also been 
reported to cause nerve damage due to apoptosis induced by MAPK 
signalling leading to structural damage of peripheral nerves [40]. 
The dose-dependent reversal of glucose neurotoxicity of high 
glucose in neuroblastoma cells by SMC may find its explanation in 
the reduced formation of cytokines that might have prevented 
induction of apoptosis via the MAPK signalling pathway. However, 
the action of SMC on MAPK activation is yet to be revealed and is 
under investigation by us. 
The main objective of the study was to investigate into the 
neuroprotective effect of saponin of Momordica cymbalaria in NB-
41A3 mouse neuroblastoma cells. The saponin was found to reduce 
significantly the expression and activity of aldose reductase in the 
cells maintained in high glucose. Intracellular sorbitol accumulation 
was also found to be reduced which is a positive indication towards 
the amelioration of neuropathic pain. The Na+K+-ATPase activity was 
found to be restored upon treatment with SMC which is beneficial 
for the proper membrane potential and nerve conduction. SMC was 
also found to have a prominent effect in the reduction of pro-
inflammatory cytokines formation in the presence of high glucose 
which explains its anti-neuro inflammatory activity.  
CONCLUSION 
In this study, we find that SMC possesses significant aldose 
reductase inhibitory activity which can prove beneficial in the 
management of neuropathy along with proper glycemic control. The 
Na+K+-ATPase activity improved in the presence of SMC which 
indicates improvement in the nerve conduction. As the 
inflammatory cytokines production also reduced considerably in the 
presence of SMC, it can be promising in the management of 
neuroinflammation and pain. 
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